sponsored
PatientsVille.com Logo

PatientsVille

Lanvis Medical Research Studies

Up-to-date List of Lanvis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lanvis Medical Research Studies

Rank Status Study
1 Not yet recruiting Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: 6-thioguanine
Outcome Measures: Change in median thiopurine metabolite index;   Toxicities;   Change in median DNA-TG
2 Recruiting Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Conditions: Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
Outcome Measures: 3-Year Event-Free Survival (EFS) rate;   Efficacy Monitoring by Patient Response
3 Recruiting Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Outcome Measures: Continuous complete remission of patients receiving high-dose and conventional dose PEG-asparaginase.;   Event-free survival;   Overall survival;   Level of minimal residual disease (MRD) on the 15th day of remission induction;   Time to CNS relapse or the last follow up since diagnosis
4 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: doxorubicin hydrochloride;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Other: laboratory biomarker analysis
Outcome Measures: Event-free survival (EFS) after initial remission;   Nelarabine toxicity assessment by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Incidence of toxicities of combination chemotherapy with vs without nelarabine as assessed by NCI CTCAE version 4.0;   Efficacy of combination chemotherapy with vs without nelarabine;   Incidence of toxicities of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;   Efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;   Incidence of CNS relapse;   Overall survival
5 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
Outcome Measures: Comparison of DFS of children with HR-ALL receiving post-Induction age adjusted ITT on an MBFM-IMHDM backbone compared to age adjusted IT MTX;   Comparison of DFS of children, adolescents, and young adults with VHR-ALL between arms;   Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR-ALL;   Toxicity and tolerability of arms II and III compared to arm I in patients with VHR-ALL;   Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with DS and HR-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM;   Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome;   Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation;   OS rate for HR-ALL patients;   OS rate for VHR-ALL patients;   Peripheral blood absolute lymphocyte count in prediction of DFS in children, adolescents, and young adults with HR-ALL;   Incidence and prognostic significance of recently discovered recurrent genomic lesions, including high CRLF2 expression, CRLF2 activating genomic lesions, JAK mutations, and IKZF1 mutations/deletions;   Prognostic significance of molecular risk classifiers using Low Density Array (LDA) Taqman cards;   Frequency of occurrence of key adverse events across all patient subgroups of HR-ALL;   Differences in the burden of therapy between HR-ALL and VHR-ALL when treated on the various arms of this study;   Comparison of drug delivery of vincristine sulfate, pegaspargase and methotrexate during Induction, Consolidation, DI, and IM II in 16-30 year olds on the control arm of the VHR study to AYAs with ALL on the C10403 adult cooperative group trial
6 Not yet recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: bortezomib;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: daunorubicin hydrochloride;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Drug: hydrocortisone sodium succinate;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: etoposide;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Outcome Measures: EFS between modified ABFM backbone with or without bortezomib in all randomized patients;   EFS;   Cumulative incidence rates;   Incidence of toxicity associated with modified standard therapy, including dexamethasone and additional pegaspargase as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   EFS between VHR T-ALL patients treated with HR BFM intensification blocks who become MRD negative and those who remain MRD positive at the end of HR Block 3;   EFS between VHR T-LLy patients treated with HR BFM intensification blocks who have partial remission (PR) or complete remission (CR) with those who do not respond (NR)
7 Recruiting Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization;   Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance;   Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens;   DFS for Down syndrome patients;   Burden of therapy in AR patients overall at different time points during and at the end of therapy;   Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy
8 Not yet recruiting Blinatumomab in Treating Younger Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: dexamethasone;   Drug: vincristine sulfate;   Drug: pegaspargase;   Drug: mitoxantrone hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: asparaginase;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: blinatumomab;   Drug: mercaptopurine;   Drug: thioguanine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: 2-year DFS of HR and IR relapse patients;   3-year DFS of LR relapse patients;   Rates of MRD positivity (> 0.01%);   Morphologic CR rate;   MRD negativity (< 0.01%) rate;   Proportion of patients that proceed to HSCT after treatment with blinatumomab (for treatment failure patients not previously receiving blinatumomab);   Feasibility of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 25% rate of grade III-IV aGVHD;   Safety of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 5% rate of treatment-related mortality (TRM)
9 Recruiting NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
Outcome Measures: Event-free survival (EFS).;   Overall survival (OS).;   Percentage of lymphoblastic cells in bone marrow at diagnosis (MDD) and at day 8 of therapy (MRD).
10 Recruiting Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: amsacrine;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Outcome Measures: Safety and efficacy of clofarabine combined with pegaspargase (phase II);   Cytotoxic efficacy of clofarabine compared with high-dose (HD) cytarabine in combination with pegaspargase (phase III);   Incidence of infectious complications after administration of daunorubicin hydrochloride vs doxorubicin hydrochloride;   Safety profiles of clofarabine and pegaspargase vs HD cytarabine and pegaspargase;   Efficacy of clofarabine and pegaspargase and HD cytarabine and pegaspargase, in terms of minimal-residual disease (MRD) vs methotrexate, cyclophosphamide, and asparaginase in study COALL-07-03;   Impact of MRD-based stratification in COALL-09 on overall survival and event-free survival in a historical comparison of previous COALL studies
11 Unknown  Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Drug: vindesine
Outcome Measures: Disease-free survival;   Event-free survival;   Overall survival
12 Recruiting International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: PEG-L-asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Drug: vindesine;   Drug: daunoxome;   Drug: fludarabine;   Radiation: Radiation Therapy
Outcome Measures: Event-free survival;   Disease-free survival;   minimal residual disease (MRD);   survival;   treatment-related mortality;   adverse events;   event-free survival;   minimal residual disease
13 Unknown  Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisolone;   Drug: teniposide;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Outcome Measures: Dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride;   Reduce therapy in low-risk patients without loss of efficacy;   Reduce neurological complications;   Reduce allergic reactions against asparaginase
14 Recruiting Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Drug: vindesine
Outcome Measures: Treatment feasibility;   Disease free survival;   Event free survival;   Overal survival;   Toxicity;   Compliance
15 Unknown  German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Condition: Adult Acute Lymphocytic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Vincristine;   Drug: daunorubicin;   Drug: Asparaginase;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: G-CSF;   Drug: Vindesine;   Drug: VP16;   Drug: Prednisolone;   Drug: Adriamycin;   Drug: Thioguanine;   Drug: VM26;   Procedure: CNS irradiation;   Procedure: Mediastinal Irradiation;   Procedure: Stem cell transplantation;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Cladribine
Outcome Measures: Remission rate, Remission duration, Disease free survival,Overall survival;   Time and dose compliance, Realisation of SCT, Toxicity according to WHO, Course of MRD
16 Recruiting Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin;   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: prednisolone;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation
Outcome Measures: Disease-free survival;   Survival;   Event-free survival;   Event-free survival within each risk group (i.e., low-risk, medium-risk, or high-risk)
17 Recruiting A Clinical Trial in Patients With BRCA Defective Tumours
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine;   Drug: Methotrexate
Outcome Measure: To determine the objective response rate to 6MP/MTX in this patient population.
18 Recruiting Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Condition: Leukemia
Interventions: Behavioral: compliance monitoring;   Behavioral: telephone-based intervention;   Drug: mercaptopurine;   Other: computer-assisted intervention;   Other: counseling intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: standard follow-up care
Outcome Measures: Adherence rate to 6MP defined as the ratio of MEMS pill container openings to the number of days that 6MP doses were prescribed during each study month;   Effect of socio-demographic and clinical characteristics as well as health beliefs/knowledge on changes in adherence with the IP
19 Recruiting Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain
Condition: Acute Chest Pain
Interventions: Other: Low-dose Cardiac CT protocol;   Other: Conventional cardiac CT protocol
Outcome Measures: Proportion of patients having hard events (death, MI) after negative low-dose CCTA findings;   Direct comparison of accuracy (sensitivity, specificity, PPV, NPV) for between low-dose and conventional cardiac CT;   Direct comparison of frequency and overall cost of additional tests such as echocardiography, treadmill test, myocardial SPECT and coronary angiography;   Total radiation dose exposed by index CT imaging and additional tests including SPECT and invasive angiography;   Total length of ED and hospital stay

These studies may lead to new treatments and are adding insight into Lanvis etiology and treatment.

A major focus of Lanvis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lanvis